RASSF1 and cancer: It is investigated in several cancer types, and RASSF1A promoter hypermethylation is observed in multiple human malignancies such as lung cancer (22.6%), pancreatic cancer (34.0%), gastric cancer (28.6%), breast cancer (28.2%), and colon cancer (28.3%) [9].